BLU-667 Demonstrates Broad Activity in RET+ Advanced Solid Tumors
April 16th 2018According to the results from a phase I study, BLU-667, a next-generation tyrosine kinase inhibitor, was well-tolerated and demonstrated clinical benefit in patients with advanced, <em>RET</em>-altered solid tumors who had progressed on previous therapies. These findings were presented April 14 to 18 at the ASCR Annual Meeting 2018 in Chicago, Illinois.
Read More
Adjuvant Pembrolizumab Significantly Reduces Risk of Recurrence in Stage III Melanoma
April 16th 2018According to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial presented at the 2018 AACR Annual Meeting and published in the <em>New England Journal of Medicine, </em>adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma.
Read More
Experts Share Their Key Takeaways from the 2018 SGO Annual Meeting
April 4th 2018Experts in the gynecologic oncology field share their key takeaways from the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held at the Hyatt Regency Resort & Convention Center in New Orleans, Louisiana, from March 24 to 27, 2018.
Watch
Safety Analysis Favors Olaparib in Meta-Analysis Comparing PARP Inhibitors in Ovarian Cancer
March 28th 2018The results of a network meta-analysis, which compared efficacy and safety findings from studies of 3 FDA-approved PARP inhibitors as maintenance therapy for patients with relapsed platinum-sensitive ovarian cancer, demonstrated that similar efficacy results were seen across the 3 PARP inhibitors, but safety results differed.
Read More
In Relapsed Ovarian Cancer, Responses Achieved With PARP/Checkpoint Inhibitor Combo
March 28th 2018According to results from the phase II MEDIOLA trial, the combination of olaparib (Lynparza), a PARP inhibitor, and durvalumab (Imfinzi), a PD-L1 inhibitor, was found to induce objective responses in over 70% of patients with relapsed, platinum-sensitive, BRCA-mutated ovarian cancer.
Read More
Durable Responses Achieved With Niraparib and Pembrolizumab Combination for Ovarian Cancer
March 27th 2018Results from a phase I/II trial indicated that durable responses could be achieved with the combination of niraparib (Zejula), a PARP inhibitor, and pembrolizumab (Keytruda), a PD-1 inhibitor, in patients with platinum-resistant/refractory ovarian cancer.
Read More
An Overview of Vigil Personalized Engineered Autologous Tumor Cells in Ovarian Cancer
March 27th 2018Rodney P. Rocconi, MD, chief of Gynecologic Oncology Service, associate director for Clinical Research, professor of Interdisciplinary Clinical Oncology, discusses a phase I trial of Vigil personalized engineered autologous tumor cells in ovarian cancer during the 2018 Society of Gynecologic Oncology Annual Meeting.
Watch
Early Promise Seen With Combo of Pembrolizumab and Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2018A combination regimen of pembrolizumab (Keytruda) and mirvetuximab soravtansine (IMGN853) induced responses in close to half of the patients in a small study of platinum-resistant ovarian cancer .
Read More
PFS Benefit Found With Added Trastuzumab in Uterine Serous Carcinoma
March 27th 2018When trastuzumab (Herceptin) was added to chemotherapy, a more than 50% improvement in progression-free survival (PFS) was observed compared with chemotherapy alone in patients with HER2-positive uterine serous carcinoma (USC), according to findings from a small randomized trial.
Read More
Efficacy Results for Trastuzumab in HER2-Positive Uterine Serous Carcinoma
March 27th 2018Alessandro D. Santin, MD, a professor of obstetrics, gynecology, and reproductive sciences at Yale School of Medicine, discusses results of a randomized phase II trial of trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab (Herceptin) in advanced or recurrent uterine serous carcinomas that overexpress HER2/neu during the 2018 Society of Gynecologic Oncology Annual Meeting.
Watch
New Approach Helps Direct Best Maintenance Therapy Choice for Patients With Ovarian Cancer
March 26th 2018The United States Food and Drug Administration approved several maintenance therapies over the last few years for the management of platinum-sensitive recurrent ovarian cancer. Bevacizumab (Avastin), TKIs, or PARP inhibitors were among the treatments used in the clinical trials leading to these approvals.
Read More
Approaches for Transitioning to Multidisciplinary Cancer Care Teams
March 26th 2018Mark S. Soberman, MD, MBA, FACS, 2017-2018 president of the Association of Community Cancer Centers (ACCC), discusses various approaches that can be used to integrate multidisciplinary healthcare programs into various healthcare settings, following a panel discussion during the ACCC 44th Annual Meeting & Cancer Center Business Summit.
Watch
Large Opioid Decrease After Gynecologic Surgery With New Restrictive Protocol
March 26th 2018A prospective study found that implementing an “ultra-restrictive” opioid prescription protocol for gynecologic surgery had led to an 89% reduction in opioid tablets dispensed at discharge and a high rate of patient satisfaction.
Read More
Early Biomarkers Found for Patients Requiring Dose Reduction With Niraparib in Ovarian Cancer
March 25th 2018In an analysis of the phase III ENGOT-OV16/NOVA study, baseline body weight and platelet counts served as early biomarkers for patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who would require dose modifications to their treatment with niraparib (Zejula).
Read More
Higher Toxicity With Checkpoint Inhibitor Treatment Found in Study of Recurrent Ovarian Cancer
March 25th 2018According to study findings presented during the 49th Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancers held in New Orleans March 24-27, clinical benefit has been found for women with recurrent ovarian cancer when using immune checkpoint inhibitors, but there was a higher rate of adverse events (AEs) than previously reported in other tumor types.
Read More
Predicting Response to PARP Inhibitor Therapy in Ovarian Cancer
March 25th 2018Michael Birrer, MD, PhD, professor of medicine in the Division of Hematology-Oncology, and Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham, discusses current data on predicting response to PARP inhibitor therapy in ovarian cancer.
Watch
Addressing Challenges in Precision Medicine and Genetic Testing in the Community
March 17th 2018Perspectives from the community, academic, and scientific settings came together during a panel discussion on precision medicine and genetic testing in the community setting at the Association of Community Cancer Centers’ 44th Annual Meeting and Cancer Center Business Summit.
Read More
Panelists Highlight Ways to Ease Transition to Value-Based Care
March 16th 2018In a panel discussion this morning during the Association of Community Cancer Center (ACCC)’s 44th Annual Meeting & Cancer Center Business Summit, experts stressed the importance of integrating team-based care to break silos and allow a continued care transition as the move continues toward value-based care.
Read More
Developing Standards for Managing Financial Toxicity
March 16th 2018Financial toxicity is increasingly recognized as an adverse event of modern oncologic treatment. In recognition of the need to guide patients through this aspect of their cancer journey, the Association of Community Cancer Centers has unveiled Financial Advocacy Services Guidelines 2018.
Read More
Experts Address Biggest Drivers of Change in Oncology Care
March 16th 2018During a panel at the Association for Community Cancer Center 44th Annual Meeting & Cancer Center Business Summit this morning, experts discussed some of the biggest drivers of change in oncology care, as well as what is in need of the most attention at the present time.
Read More
Ramucirumab/Durvalumab Combo Produces Antitumor Activity in Gastric, GEJ Cancer
January 25th 2018According to findings presented at the 2018 Gastrointestinal Cancers Symposium, the combination of the VEGFR-2 inhibitor ramucirumab (Cyramza) plus the anti–PD-L1 agent durvalumab (Imfinzi) demonstrated antitumor activity in a phase Ia/b study of patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Read More
Sequencing Regorafenib Before Cetuximab Leads to Improved Survival in mCRC
January 24th 2018Superior overall survival was induced with sequencing regorafenib (Stivarga) before cetuximab (Erbitux) compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy, according to findings from the phase II REVERCE study presented at the 2018 Gastrointestinal Cancers Symposium.
Read More
Cabozantinib Demonstrates OS, PFS Improvement in Advanced HCC
January 23rd 2018According to findings from the phase III CELESTIAL trial released ahead of the 2018 Gastrointestinal Cancers Symposium, cabozantinib (Cabometyx) improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.
Read More
Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced GISTs
January 22nd 2018Patients with heavily pretreated gastrointestinal stromal tumors responded to treatment with nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy), according to findings of a randomized phase II study presented at the 2018 Gastrointestinal Cancers Symposium.
Read More
Acupuncture Effective in Reducing AI-Associated Joint Pain in Women With Breast Cancer
January 9th 2018According to data from a randomized phase III trial presented at the 2017 San Antonio Breast Cancer Symposium, a mix of traditional and customized acupuncture techniques were effective in reducing pain and stiffness associated with aromatase inhibitor therapy in women with early-stage breast cancer.
Read More